ABSTRACT
Historical control data on rodent developmental toxicity studies, performed between 1994 and 2010, were obtained from 19 laboratories in Japan, including 10 pharmaceutical and chemical companies and nine contract research organizations. Rats, mice, and hamsters were used for developmental toxicity studies. Data included maternal reproductive findings at terminal cesarean sections and fetal findings including the spontaneous incidences of external, visceral, and skeletal anomalies. No noticeable differences were observed in maternal reproductive data between laboratories. Inter-laboratory variations in the incidences of fetuses with anomalies appeared to be due to differences in the selection of observation parameters, observation criteria, classification of the findings, and terminology of fetal alterations. Historical control data are useful for the appropriate interpretation of experimental results and evaluation of the effects of chemical on reproductive and developmental toxicities.
Subject(s)
Drug Evaluation, Preclinical/history , Animals , Control Groups , Cricetinae , Female , Growth and Development/drug effects , History, 20th Century , History, 21st Century , Male , Mice , Pregnancy , Rats , Reproducibility of Results , Research DesignABSTRACT
The development of safer drugs is a high priority for pharmaceutical companies. Among the various toxicities caused by drugs, cardiotoxicity is an important issue because of its lethality. In addition, cardiovascular toxicity leads to the attrition of many drug candidates in both preclinical and clinical phases. Although histopathological and blood chemistry examinations are the current gold standards for detecting cardiotoxicity in preclinical studies, the large number of withdrawals from clinical studies owing to safety problems indicate that a more sensitive tool is required. We recently identified 32 genes that were candidate genomic biomarkers for cardiotoxicity in rats. Based on their functions, the present study focused on 8 of these 32 genes (Spp1, Fhl1, Timp1, Serpine1, Bcat1, Lmcd1, Rnd1 and Tgfb2). Diagnostic accuracy for the genes was determined by a receiver-operating characteristic (ROC) analysis using more cardiotoxic and non-cardiotoxic compounds. In addition, an optimized support vector machine (SVM) model that was composed of Spp1 and Timp1 was newly constructed. This new multi-gene model exhibited a much higher diagnostic accuracy than that observed for plasma cardiac troponin I (cTnI), which is one of the most useful plasma biomarkers for cardiotoxicity detection. Furthermore, we determined that this multi-gene model could predict potential cardiotoxicity in rats in the absence of any cardiac histopathological lesions or elevations of plasma cTnI. Overall, this multi-gene model exhibited advantages over classic tools commonly used for cardiotoxicity evaluations in rats. Our current results suggest that application of the model could potentially lead to the production of safer drugs.
Subject(s)
Cardiotoxins/chemistry , Drug Evaluation, Preclinical , Heart Diseases/genetics , Heart Diseases/pathology , Animals , Biomarkers/blood , Co-Repressor Proteins/blood , Co-Repressor Proteins/genetics , Drug-Related Side Effects and Adverse Reactions/pathology , Gene Expression Profiling , Genetic Markers , Heart Diseases/chemically induced , Heart Diseases/diagnosis , LIM Domain Proteins/blood , LIM Domain Proteins/genetics , Male , Multigene Family , Muscle Proteins/blood , Muscle Proteins/genetics , Osteopontin/blood , Osteopontin/genetics , Pharmaceutical Preparations , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activator Inhibitor 1/genetics , ROC Curve , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-1/blood , Tissue Inhibitor of Metalloproteinase-1/genetics , Transaminases/blood , Transaminases/genetics , Transforming Growth Factor beta2/blood , Transforming Growth Factor beta2/genetics , Troponin I/blood , Up-Regulation , rho GTP-Binding Proteins/blood , rho GTP-Binding Proteins/geneticsABSTRACT
Cardiotoxicity and musculoskeletal toxicity can be life-threatening, and thus have strong impact on both the development and marketing of drugs. Because the conventional biomarkers such as aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) have low detection power, there has been increasing interest in developing biomarkers with higher detection power. The current study examined the usefulness of several promising biomarkers, cardiac and skeletal muscle troponins (cTnI, cTnT and sTnI), fatty acid binding protein 3 (FABP3) and myosin light chain 3 (MYL3), and compared the obtained data to AST, LDH and CK in rat models treated with various myotoxic and non-myotoxic compounds (isoproterenol, metaproterenol, doxorubicin, mitoxantrone, allylamine, cyclosporine A, cyclophosphamide, aminoglutethimide, acetaminophen, methapyrilene, allylalcohol and α-naphthylisothiocyanate). These promising biomarkers were found to be superior to the conventional biomarkers, as they had a specific and abundant distribution within the heart and/or skeletal muscles; exhibited a positive correlation between the amplitude of increases and the degree of pathological alterations; had higher diagnostic accuracy for detecting pathological alterations; and had the additive effect of improving the diagnostic accuracy of conventional biomarkers. However, these promising biomarkers have several drawbacks including a rapid clearance, the fact that they are affected by renal dysfunction, and different reactivity to the mode of action of individual myotoxicants. In conclusion, the promising biomarkers cTnI, cTnT, FABP3, MYL3, and sTnI demonstrated sensitivity and specificity for cardiac and skeletal myotoxicity that was superior to those of conventional biomarkers, while we should pay attention to the drawbacks of these biomarkers when used in toxicity studies.
Subject(s)
Fatty Acid-Binding Proteins/metabolism , Heart Diseases/diagnosis , Muscular Diseases/diagnosis , Myosin Light Chains/metabolism , Troponin/metabolism , Animals , Area Under Curve , Aspartate Aminotransferases/metabolism , Biomarkers/metabolism , Creatine Kinase/metabolism , Fatty Acid Binding Protein 3 , L-Lactate Dehydrogenase/metabolism , Male , Muscle, Skeletal/metabolism , Myocardium/metabolism , Rats , Rats, Sprague-Dawley , Sensitivity and Specificity , Tissue DistributionABSTRACT
The immuno-suppressant Leflunomide, a potent inhibitor of dihydroorotate dehydrogenase (DHODH) and tyrosine kinases, is teratogenic in laboratory animals. To better understand its teratogenic mechanism, pregnant mice (CD-1) received a single dose of 70mg/kg Leflunomide, or vehicle control, by gastric intubation on gestation day 10. Gene expression was evaluated in the pooled fore- and hindlimb buds of embryos 4 and 24h post-treatment. The down-regulation of cholesterol biosynthesis-related genes was observed but could not be correlated with teratogenicity, since Leflunomide did not alter cholesterol concentration in limb bud. Leflunomide inhibited the mitosis of limb mesenchymal cells, which may be linked to DHODH inhibition as well as a potential effect on tyrosine kinases that mediate cytokine and growth factor signaling and that may be responsible for the Leflunomide's teratogenicity.
Subject(s)
Immunosuppressive Agents/toxicity , Isoxazoles/toxicity , Limb Deformities, Congenital/chemically induced , Limb Deformities, Congenital/genetics , Oligonucleotide Array Sequence Analysis , Animals , Cell Division/drug effects , Cholesterol/analysis , Cholesterol/biosynthesis , Cholesterol/genetics , Dihydroorotate Dehydrogenase , Enzyme Inhibitors/toxicity , Female , Gestational Age , Isoxazoles/administration & dosage , Leflunomide , Limb Buds/chemistry , Mesoderm/cytology , Mice , Mice, Inbred ICR , Mitotic Index , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Pregnancy , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Leflunomide is an immunosuppressant drug displaying teratogenicity in mice, rats, and rabbits. Its immunosuppressive effect occurs via inhibition of dihydroorotate dehydrogenase (DHODH) and tyrosine kinases. In this study, we coadministered Leflunomide and uridine, a precursor substance of pyrimidine nucleotides, to pregnant CD-1 mice, and examined whether or not a decreased level of intracellular pyrimidine nucleotides with inhibition of DHODH is related to the teratogenicity of Leflunomide. Then we examined the alteration of the nucleotide level in fetal tissue by Leflunomide and the effect of coadministered uridine. We administered Leflunomide with or without uridine to pregnant mice on gestation day 10, and used the vehicle of Leflunomide as a control. Leflunomide caused multiple malformations in all fetuses, but coadministration with uridine inhibited most of its teratogenicity. Leflunomide decreased the concentration of pyrimidine nucleotides, not purine nucleotides, whereas uridine coadministered with Leflunomide partially restored the level of pyrimidine nucleotides. These results indicate that the inhibitory effect of DHODH activity is related to the teratogenicity of Leflunomide.
Subject(s)
Immunosuppressive Agents/antagonists & inhibitors , Immunosuppressive Agents/toxicity , Isoxazoles/antagonists & inhibitors , Isoxazoles/toxicity , Teratogens , Uridine/pharmacology , Abnormalities, Drug-Induced/pathology , Animals , Dihydroorotate Dehydrogenase , Embryonic Development/drug effects , Female , Fetal Viability/drug effects , Fetus/drug effects , Fetus/metabolism , Fetus/pathology , Leflunomide , Mice , Mice, Inbred ICR , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Oxidoreductases Acting on CH-CH Group Donors/metabolism , Pregnancy , Pyrimidine Nucleotides/metabolismABSTRACT
Leflunomide has inhibitory effects on dihydroorotate-dehydrogenase activity and protein tyrosine kinase activity. In the present study, a single dose of 50 mg/kg Leflunomide was administered to pregnant mice on one of gestation days (GD)6-11. Characteristic external malformations were craniofacial defects following dosing on GD7, cleft palate on GD9, cleft palate and limb and tail deformities on GD10, and limb deformities on GD11. Skeletal examination revealed cervical to caudal vertebral malformations after treatment on GD7, GD8, GD9 or GD10. In the viscera, cardiovascular deformities were observed in the GD7 and GD9 Leflunomide-treated groups. These results demonstrate that multiple malformations were seen in various organs and most of the malformations observed appeared to be developmental stage-specific responses to Leflunomide treatment.
Subject(s)
Abnormalities, Drug-Induced , Abnormalities, Multiple/pathology , Embryo, Mammalian/drug effects , Fetal Viability/drug effects , Immunosuppressive Agents/toxicity , Isoxazoles/toxicity , Adjuvants, Immunologic/toxicity , Animals , Critical Period, Psychological , Embryo Loss , Embryo, Mammalian/cytology , Female , Gestational Age , Leflunomide , Male , Mice , Mice, Inbred ICR , PregnancyABSTRACT
Cephaloridine (CER) is a classical beta-lactam antibiotic that has long served as a model drug for the study of cephalosporin antibiotic-induced acute tubular necrosis. In the present study, we analyzed gene expression profiles in the kidney of rats given subtoxic and toxic doses of CER to identify gene expression alterations closely associated with CER-induced nephrotoxicity. Male Fischer 344 rats were intravenously injected with CER at three different dose levels (150, 300, and 600 mg/kg) and sacrificed after 24 h. Only the high dose (600 mg/kg) caused mild proximal tubular necrosis and slight renal dysfunction. Microarray analysis identified hundreds of genes differentially expressed in the renal cortex following CER exposure, which could be classified into two main groups that were deregulated in dose-dependent and high dose-specific manners. The genes upregulated dose dependently mainly included those involved in detoxification and antioxidant defense, which was considered to be associated with CER-induced oxidative stress. In contrast, the genes showing high dose-specific (lesion-specific) induction included a number of genes related to cell proliferation, which appeared to reflect a compensatory response to CER injury. Of the genes modulated in both manners, we found many genes reported to be associated with renal toxicity by other nephrotoxicants. We could also predict potential transcription regulators responsible for the observed gene expression alterations, such as Nrf2 and the E2F family. Among the candidate gene biomarkers, kidney injury molecule 1 was markedly upregulated at the mildly toxic dose, suggesting that this gene can be used as an early and sensitive indicator for cephalosporin nephrotoxicity. In conclusion, our transcriptomic data revealed several characteristic expression patterns of genes associated with specific cellular processes, including oxidative stress response and proliferative response, upon exposure to CER, which may enhance our understanding of the molecular mechanisms behind cephalosporin antibiotic-induced nephrotoxicity.
Subject(s)
Anti-Bacterial Agents/toxicity , Cephaloridine/toxicity , Nephrosis/chemically induced , Nephrosis/metabolism , Animals , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Gene Expression Profiling , Genetic Markers , Male , Nephrosis/genetics , Nephrosis/pathology , Rats , Rats, Inbred F344ABSTRACT
Leflunomide is an immunosuppressive agent that inhibits de novo synthesis of pyrimidine nucleotides and the activity of protein tyrosine kinase. This study examined the teratogenicity of Leflunomide in mice. Pregnant mice were treated orally with Leflunomide at a dose of 10, 30 or 70 mg/kg/day from day 6 to 15 of pregnancy. At 70 mg/kg, all embryos were resorbed and no live fetuses were detected. At 30 mg/kg, Leflunomide reduced fetal viability, and increased the incidence of multiple external, skeletal and visceral malformations. Characteristic external malformations were neural tube defects, cleft palate and tail deformities. Limb malformations were observed in a small number of fetuses. Skeletal examinations revealed malformations of cervical to sacral vertebrae, ribs and sternebrae. In the viscerae, the main anomalies were membranous ventricular septum defect and persistent truncus arteriosus. The results of this study indicate that Leflunomide administered at 30 mg/kg on days 6 to 15 of pregnancy can induce craniofacial malformations and deformities of the axial skeleton, heart and great vessels in mice.